These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

870 related items for PubMed ID: 29220542

  • 1. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
    Reich K, Gooderham M, Bewley A, Green L, Soung J, Petric R, Marcsisin J, Cirulli J, Chen R, Piguet V.
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
    [Abstract] [Full Text] [Related]

  • 2. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
    Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, Day RM, Goncalves J, Shah K, Piguet V, Soung J.
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
    Rich P, Gooderham M, Bachelez H, Goncalves J, Day RM, Chen R, Crowley J.
    J Am Acad Dermatol; 2016 Jan; 74(1):134-42. PubMed ID: 26549249
    [Abstract] [Full Text] [Related]

  • 5. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
    Ohtsuki M, Okubo Y, Komine M, Imafuku S, Day RM, Chen P, Petric R, Maroli A, Nemoto O.
    J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
    Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM, Girolomoni G, Gottlieb AB.
    Br J Dermatol; 2015 Dec; 173(6):1387-99. PubMed ID: 26357944
    [Abstract] [Full Text] [Related]

  • 7. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.
    Thaçi D, Kimball A, Foley P, Poulin Y, Levi E, Chen R, Feldman SR.
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):498-506. PubMed ID: 27538241
    [Abstract] [Full Text] [Related]

  • 8. Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
    Sobell JM, Foley P, Toth D, Mrowietz U, Girolomoni G, Goncalves J, Day RM, Chen R, Yosipovitch G.
    Acta Derm Venereol; 2016 May; 96(4):514-20. PubMed ID: 26837052
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study.
    Van Voorhees AS, Stein Gold L, Lebwohl M, Strober B, Lynde C, Tyring S, Cauthen A, Sofen H, Zhang Z, Paris M, Wang Y.
    J Am Acad Dermatol; 2020 Jul; 83(1):96-103. PubMed ID: 32032692
    [Abstract] [Full Text] [Related]

  • 10. Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week Randomized, Placebo-Controlled Trial Results.
    Nguyen CM, Leon A, Danesh M, Beroukhim K, Wu JJ, Koo J.
    J Drugs Dermatol; 2016 Mar; 15(3):272-6. PubMed ID: 26954311
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial.
    Fiorillo L, Becker E, de Lucas R, Belloni-Fortina A, Armesto S, Elewski B, Maes P, Oberoi RK, Paris M, Zhang W, Zhang Z, Arkin L.
    J Am Acad Dermatol; 2024 Jun; 90(6):1232-1239. PubMed ID: 38266683
    [Abstract] [Full Text] [Related]

  • 12. Open-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast.
    Bagel J, Samad AS, Stolshek BS, Aras GA, Chung JB, Kricorian G, Kircik LH.
    J Drugs Dermatol; 2018 Oct 01; 17(10):1078-1082. PubMed ID: 30365588
    [Abstract] [Full Text] [Related]

  • 13. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
    Bissonnette R, Pariser DM, Wasel NR, Goncalves J, Day RM, Chen R, Sebastian M.
    J Am Acad Dermatol; 2016 Jul 01; 75(1):99-105. PubMed ID: 27021239
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.
    Papp KA, Kaufmann R, Thaçi D, Hu C, Sutherland D, Rohane P.
    J Eur Acad Dermatol Venereol; 2013 Mar 01; 27(3):e376-83. PubMed ID: 23030767
    [Abstract] [Full Text] [Related]

  • 15. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
    Gottlieb AB, Matheson RT, Menter A, Leonardi CL, Day RM, Hu C, Schafer PH, Krueger JG.
    J Drugs Dermatol; 2013 Aug 01; 12(8):888-97. PubMed ID: 23986162
    [Abstract] [Full Text] [Related]

  • 16. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
    Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, Hu C, Stevens RM, Day RM, Gordon KB, Korman NJ, Griffiths CE.
    J Am Acad Dermatol; 2015 Jul 01; 73(1):37-49. PubMed ID: 26089047
    [Abstract] [Full Text] [Related]

  • 17. Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study.
    Strand V, Fiorentino D, Hu C, Day RM, Stevens RM, Papp KA.
    Health Qual Life Outcomes; 2013 May 10; 11():82. PubMed ID: 23663752
    [Abstract] [Full Text] [Related]

  • 18. Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis.
    Armstrong A, Levi E.
    J Drugs Dermatol; 2017 Dec 01; 16(12):1240-1245. PubMed ID: 29240859
    [Abstract] [Full Text] [Related]

  • 19. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
    Papadavid E, Rompoti N, Theodoropoulos K, Kokkalis G, Rigopoulos D.
    J Eur Acad Dermatol Venereol; 2018 Jul 01; 32(7):1173-1179. PubMed ID: 29388335
    [Abstract] [Full Text] [Related]

  • 20. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Keating GM.
    Drugs; 2017 Mar 01; 77(4):459-472. PubMed ID: 28213862
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.